- Conditions
- Rheumatoid Arthritis
- Interventions
- secukinumab (AIN457), placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 8
- States / cities
- Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Rheumatoid Arthritis
- Interventions
- AIN457, Placebo, Abatacept
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 44
- States / cities
- Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Secukinumab (AIN457), Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 39
- States / cities
- Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- AIN457 150mg, AIN457 300mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 967 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 33
- States / cities
- Fresno, California • Pasadena, California • Sacramento, California + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Secukinmab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 13
- States / cities
- Mesa, Arizona • Peoria, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
- Conditions
- Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
- Interventions
- Secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Boise, Idaho • Cincinnati, Ohio • Portland, Oregon
- Conditions
- Moderate to Severe Palmoplantar Psoriasis
- Interventions
- secukinumab 150 mg, secukinumab 300 mg, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Secukinumab, Placebo (Pbo)
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
- Conditions
- Uveitis
- Interventions
- AIN457, Placebo
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Arlington, Texas
- Conditions
- Uveitis
- Interventions
- AIN457, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Cambridge, Massachusetts • Slingerlands, New York + 2 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- secukinumab 150 mg, placebo to secukinumab 150 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- Placebo, secukinumab (AIN457), etanercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab (AIN457), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 21
- States / cities
- Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Secukinumab (AIN457), Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 25
- States / cities
- Peoria, Arizona • Santa Monica, California • Upland, California + 20 more
- Conditions
- Plaque-type Psoriasis
- Interventions
- secukinumab 150mg, secukinumab 10mg/kg i.v. regimen
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more